Optum Research Database Proportion of asthma patients with prescription fills for rescue and controller medications by year,

Similar documents
Disclosure Statement. Epidemiological Data

Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes

THE COPD PRESCRIBING TOOL

Global Initiative for Asthma (GINA) What s new in GINA 2015?

2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017

Asthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care

Drug Class Monograph

2014 Physician Quality Reporting System Data Collection Form: Asthma (for patients aged 5-64)

Global Initiative for Asthma (GINA) What s new in GINA 2017?

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Long Term Care Formulary RS -29

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]

April 10 th, Bond Street, Toronto ON, M5B 1W8

2. Does the patient have chronic urticaria? Y N

Section II: Detailed Measure Specifications

COPD Update. Muhammad Talha Khan MD. COPD Exacerbations. COPD Clinical Importance. COPD Pathophysiology. Overview/Objectives

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized

A Study of Prescription Pattern in the Management of COPD in a Tertiary Care Hospital.

Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)

Drug Effectiveness Review Project Summary Report

A multitude of devices

Doctor of Medicine. Alastair Stewart Dept. of Pharmacology 8 th Floor, Medical Building Rm. N802

PFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA

Update on Pulmonary Diseases. Jeffrey Lessar, MD

Asthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital

Wirral COPD Prescribing Guidelines

COPD: Current Medical Therapy

COPD: A Renewed Focus. Disclosures

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.

Three s Company - The role of triple therapy in chronic obstructive pulmonary

Algorithm for the use of inhaled therapies in COPD Version 2 May 2017

New Therapies for Asthma

Design - Multicentre prospective cohort study. Setting UK Community Pharmacies within one CCG area within the UK

LAMA Products for the Treatment of COPD

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46. Line of Business: Medicaid

«Impact of a pharmaceutical intervention to improve adherence of inhaled medication in asthma and COPD patients»

Current Approaches to Asthma & COPD

requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

GSK Medicine: salmeterol, Salmeterol+Fluticasone proprionate, fluticasone propionate, beclomethasone

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Class Update: Asthma / COPD Medications

Supplementary appendix

Chronic obstructive pulmonary disease

Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide

AND COPD ADVANCES IN COMBINATION THERAPY FOR ASTHMA. Jan Lotvall. Editor. Krefting Research Centre, University of Gothenburg,

New TLD Indication: Asthma RELIEF-1 Study. Nick ten Hacken, MD Study Co-Principal Investigator

Biologic Agents in the treatment of Severe Asthma

SABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA

Algorithm for the use of inhaled therapies in COPD

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.

David M Kern 1*, Jill Davis 2, Setareh A Williams 3, Ozgur Tunceli 1, Bingcao Wu 1, Sally Hollis 4, Charlie Strange 5 and Frank Trudo 2

What s new in Asthma? Dr Alexandra Nanzer-Kelly Consultant Respiratory Physician Royal Brompton and Harefield Hospitals

Evaluation of Asthma Management in Middle EAst North Africa Adult population

Revefenacin (TD-4208) Phase 3 Efficacy Results

Using Big Data to Assess Prescribing Patterns in Greece: The Case of Chronic Obstructive Pulmonary Disease

TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department

Changing Landscapes in COPD New Zealand Respiratory Conference

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

Setting The setting was the community. The economic study was carried out in New Jersey, USA.

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum

Case approach in Asthma and COPD. Assoc.Prof.Sunee Lertsinudom BSc.Grad.Diplo.BCP. Department of Clinical pharmacy Khonkaen University

Decline In lung-function Among Patients with chronic obstructive Lung disease On maintenance therapy (DIAPLO)

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Position within the Organisation

New Drug Evaluation: Olodaterol oral inhalation solution (Striverdi Respimat)

The Acute & Maintenance Treatment of Asthma via Aerosolized Medications

Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists

The National Asthma Education and Prevention Program s

Prescribing guidelines: Management of COPD in Primary Care

RightBreathe to help with inhaler prescribing and technique

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years

Original Research. Key words: Chronic obstructive pulmonary disease, LAMA, LABA, tiotropium, salmeterol, formoterol

RESPIRATORY SYSTEM - PHARMACOLOGY-

Asthma COPD Update 2018

Changing Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?

News on Evidence-Based Care Fourth Quarter 2013 Volume 5 Issue 4

Tiotropium: Do the findings of a CV safety signal in the meta-analyses have implications for all drugs to treat COPD?

DUPIXENT (dupilumab) subcutaneous injection

Asthma Treatment Guideline for Adults (aged 17 and over)

What is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing

Chronic Obstructive Pulmonary Diseases: 2 Novartis Pharmaceuticals Company, East Hanover, New Jersey. 3 KMK Consulting Inc., Florham Park, New Jersey

Adherence to asthma controller medication regimens

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital

COPD/Asthma. Prudence Twigg, AGNP

Evidence Review for Prescribing Clinical Network

RESPIRATORY CARE IN GENERAL PRACTICE

CHALLENGES OF REAL LIFE ASTHMA MANAGEMENT. Dr Chris Lewis Respiratory Physician and Director of Prevocational Training Auckland District Health Board

Who can get most benefit

Global Initiative for Asthma (GINA) What s new in GINA 2016?

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

#POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA

Transcription:

ASTHMA CHART 1 Optum Research Database Proportion of asthma patients with prescription fills for rescue and controller medications by year, 215-216 7 6 5 4 3 2 1 1 Controller medication 1 Rescue medication No controller or rescue medication 215 44.4 65.9 26.2 216 42. 62.8 29.3 In 215, 44.4% of asthma patients had a controller medication prescription fill and 65.9% had a fill for a rescue medication. Results were similar in 216. More than a quarter of patients diagnosed with asthma did not have any asthma-related medication fills in each year. 1. At least one asthma diagnosis in any position; and A total of 65,751 and 91,214 enrollees met the above criteria in 215 and 216, respectively. The increase in patient counts from 215 to 216 is due in part to the change from ICD-9 to ICD-1. The percentages in the graph do not sum to 1% because some patients filled prescriptions for multiple rescue medication classes.

ASTHMA CHART 2 Optum Research Database Proportion of asthma patients with prescription fills for controller medications classes by year, 215-216 7 6 5 4 3 2 1 ICS ICS/LABA LABA LAMA LM MAST METH MONOC No controller medication 215 14.6 2.8.5 6.3 18.3..7.3 55.7 216 11.6 21.8.4 7. 16.7..6.3 58. The most commonly filled controller medications were fixed dose ICS/ LABA followed by LM, ICS and LAMA. More than half of asthma patients did not have any asthma-related controller medication fills in each year. ICS inhaled corticosteroid; LABA long-acting beta agonist; LAMA long-acting muscarinic antagonist; LM leukotriene modifiers; MAST mast cell stabilizers; METH methylxanthines MONOC monoclonal antibodies (IL-5 inhibitors, anti-ige) 1. At least one asthma diagnosis in any position; and A total of 65,751 and 91,214 enrollees met the above criteria in 215 and 216, respectively. The increase in patient counts from 215 to 216 is due in part to the change from ICD-9 to ICD-1. The percentages in the graph do not sum to 1% because some patients filled prescriptions for multiple controller medication classes.

ASTHMA CHART 3 Optum Research Database Proportion of asthma patients with prescription fills for rescue medications classes by year, 215-216 6 5 4 3 2 1 OCS SABA SAMA SAMA/SABA No rescue medication 215 37.1 52.5 1.4 6.1 34.1 216 36.3 48.1 1.4 6.8 37.2 Among patients diagnosed with asthma, 52.5% and 48.1% had at least one pharmacy fill for a SABA medication in 215 and 216, respectively. More than one-third of asthma patients had at least one pharmacy fill for an OCS in each year, and more than one-third did not have any pharmacy fills for rescue medications. OCS systemic corticosteroids; SABA short-acting beta agonist SAMA short-acting muscarinic antagonist 1. At least one asthma diagnosis in any position; and A total of 65,751 and 91,214 enrollees met the above criteria in 215 and 216, respectively. The increase in patient counts from 215 to 216 is due in part to the change from ICD-9 to ICD-1. The percentages in the graph do not sum to 1% because some patients filled prescriptions for multiple rescue medication classes.

COPD CHART 4 Optum Research Database Proportion of COPD patients with prescription fills for rescue and controller medications by year, 215-216 7 6 5 4 3 2 1 1 Controller medication 1 Rescue medication No controller or rescue medication 215 34.3 54.6 39.1 216 35.9 56.6 36.9 In 215, 34.3% of COPD patients had a controller medication prescription fill and 54.6% had a fill for a rescue medication. Results were similar in 216. More than a third of patients diagnosed with COPD did not have any COPD-related medication fills in each year. 1. At least one COPD diagnosis in any position; and A total of 354,2 and 446,85 enrollees met the above criteria in 215 and 216, respectively. The increase in patient counts from 215 to 216 is due in part to the change from ICD-9 to ICD-1. The percentages in the graph do not sum to 1% because some patients filled prescriptions for controller and rescue medications.

COPD CHART 5 Optum Research Database Proportion of COPD patients with prescription fills for controller medication classes by year, 215-216 7 6 5 4 3 2 1 ICS ICS/LABA LABA LAMA LAMA/LABA METH PDE No controller medication 215 6. 22.9 1.2 14.7 1.1 1.1.5 65.7 216 5.3 24.8 1. 14.5 2.5 1..6 64.1 Among enrollees diagnosed with COPD, the most commonly filled class of controller medication was an ICS/LABA followed by LAMA. In each year, nearly one quarter of COPD patients had pharmacy fills for an ICS/LABA and roughly 15% of COPD patients had at least one pharmacy fill for a LAMA. ICS inhaled corticosteroid; LABA long-acting beta agonist LAMA long-acting muscarinic antagonist; METH methylxanthines; PDE phosphodiesterase-4 inhibitors Approximately 65% of COPD patients did not have any pharmacy fills for controller medications in 215 or 216. 1. At least one COPD diagnosis in any position; and A total of 354,2 and 446,85 enrollees met the above criteria in 215 and 216, respectively. The increase in patient counts from 215 to 216 is due in part to the change from ICD-9 to ICD-1. The percentages in the graph do not sum to 1% because some patients filled prescriptions for multiple controller medication classes.

COPD CHART 6 Optum Research Database Proportion of COPD patients with prescription fills for rescue medication classes by year, 215-216 5 45 4 35 3 25 2 15 1 5 OCS SABA SAMA SAMA/SABA No rescue medication 215 34.4 36.8 2.2 11.3 45.4 216 35.9 38.4 2.2 11.8 43.4 Among enrollees diagnosed with COPD, 36.8% and 38.4% had at least one pharmacy fill for a SABA medication in 215 and 216, respectively. Approximately 35% of COPD patients had at least one pharmacy fill for an OCS in each year. In 215 and 216, respectively, 45.4% and 43.4% of COPD patients did not have any pharmacy fills for rescue medications. OCS systemic corticosteroids; SABA short-acting beta agonist; SAMA short-acting muscarinic antagonist 1. At least one COPD diagnosis in any position; and A total of 354,2 and 446,85 enrollees met the above criteria in 215 and 216, respectively. The increase in patient counts from 215 to 216 is due in part to the change from ICD-9 to ICD-1. The percentages in the graph do not sum to 1% because some patients filled prescriptions for multiple rescue medication classes. WF51132